Orthopaedic surgery in haemophilia patients with inhibitors: A practical guide to haemostatic, surgical and rehabilitative care

Haemophilia

Volumn 15, Issue 1, 2009, Pages 227-239

  Teitel, J M ^a   Carcao, M ^b   Lillicrap, D ^c   Mulder, K ^d   Rivard, G E ^e   St louis, J ^f   Smith, F ^g   Walker, I ^h   Zourikian, N ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Factor VIII inhibitors; Guidelines; Inhibitor bypassing agents; Orthopaedic surgery

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; HYALURONIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; TRANEXAMIC ACID;

ARTHRODESIS; ARTHROPATHY; ARTHROPLASTY; ARTHROTOMY; ARTICLE; CAUTERIZATION; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; ELECTIVE SURGERY; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; MOVEMENT THERAPY; ORTHOPEDIC SURGERY; PHYSIOTHERAPY; PLASMAPHERESIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REHABILITATION CARE; SINGLE DRUG DOSE; SUBSTITUTION THERAPY; SURGICAL TECHNIQUE; SYNOVECTOMY; THROMBOSIS; WATCHFUL WAITING;

EID: 63049110965     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01840.x     Document Type: Article

References (76)

1. Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood 2004; 103: 2467-73.
2. Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American college of chest physicians task force. Chest 2006; 129: 174-81.
3. World Federation of Hemophilia. Guidelines for the Management of Hemophilia. 2005. Available at: http://www.wfh.org/2/docs/Publications/ Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf accessed on 25 November 2007.
4. Soucie J, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42.
5. Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
6. O'Marcaigh AS, Schmalz BJ, Shaughnessy WJ et al. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. Mayo Clin Proc 1994; 69: 641-4.
7. Ingerslev J, Friedman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 118-23.
8. Scharf R, Kucharski W, Nowak T. Surgery in hemophilia A patients with factor VIII inhibitor: 10-year experience. World J Surg 1996; 20: 1171-81.
9. Tagariello G, De Biasi E, Gajo GB et al. Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: Experience of two cases. Haemophilia 2000; 6: 581-3.
10. Santagostino E, Morfini M, Rocino A et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
11. Mehta S, Nelson CL, Konkle BA et al. Total knee arthroplasty using recombinant factor VII in hemophilia-A patients with inhibitors: A report of three cases. J Bone Joint Surg Am 2004; 86-A: 2519-21.
12. Slaoui M, Lambert T, Stieltjes N et al. Intestinal surgery with activated recombinant factor VII prophylaxis in patients with haemophilia A and high responding inhibitors: A report of five cases. Blood Coagul Fibrinolysis 2004; 15: 687-91.
13. Tjønnfjord GE, Brinch L, Gedde-Dahl T et al. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
14. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopedic surgery for hemophilia patients with inhibitors: New opportunities. Semin Hematol 2004; 41 (Suppl 1): 109-16.
15. Goddard N. Case studies: Orthopedic surgery in adult patients with haemophilia A with inhibitors. Haemophilia 2005; 11 (Suppl 1): 32-7.
16. Solimeno LP, Perfetto OS, Pasta G et al. Total joint replacement in patients with inhibitors. Haemophilia 2006; 12 (Suppl 3): 113-6.
17. Wallny TA, Scholz DT, Oldenburg J et al. Osteoporosis in haemophilia -an underestimated comorbidity? Haemophilia 2007; 13: 79-84.
18. Jones CA, Beaupre LA, Johnston DWC et al. Total joint arthroplasties: current concepts of patient outcomes after surgery. Clin Geriatr Med 2005; 21: 527-41.
19. Hay CR, Baglin TP, Collins PW et al. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors'Organization (UKHCDO). Br J Haematol 2000; 111: 78-90.
20. Carcao M, St Louis J, Poon MC et al. Rituximab for congenital hemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006; 12: 7-18.
21. Dunkley S, Kershaw G, Young G et al. Rituximab treatment of mild haemophilia A with inhibitors: A proposed treatment protocol. Haemophilia 2006; 12: 663-7.
22. Rivard GE, St LJ, Lacroix S et al. Immunoadsorption for coagulation factor inhibitors: A retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia 2003; 9: 711-6.
23. Freiburghaus C, Benrtorp E, Ekman M et al. Immunoadsorption for removal of inhibitors: Update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
24. Habermann B, Hochmuth K, Hovy L et al. Management of haemophilic patients with inhibitors in major orthopedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): A single center experience. Haemophilia 2004; 10: 705-12.
25. Rodriguez-Merchan EC, Goddard NJ. General principles in orthopaedic surgery of haemophilia. In: Rodriguez-Merchan EC, Goddard NJ, Lee CA, eds. Musculoskeletal Aspects of Haemophilia. London: Blackwell Science, 2000: 13-7.
26. Fernandez-Palazzi F, Viso R, Boadas A, Ruiz-Sáez A, Caviglia H, De Bosch NB. Intra-articular hyaluronic acid in the treatment of haemophilic chronic arthropathy. Haemophilia 2002; 8: 375-81.
27. Ragni M. Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. J Arthroplasty 1995; 10: 716-21.
28. Kavakli K. Fibrin glue and clinical impact on haemophilia care. Haemophilia 1999; 5: 392-6.
29. Hino M, Ishiko O, Honda KI et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000; 108: 194-5.
30. Muntean W, Zenz W, Edlinger G, Beitzke A. Severe bleeding due to factor V inhibitor after repeated operations using fibrin sealant containing bovine thrombin. Thromb Haemost 1997; 77: 1223.
31. Girolami A, Scandellari R, Zanon E et al. Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases. J Thromb Thrombolysis 2006; 21: 279-84.
32. Rodriguez-Merchan EC. Methods to treat chronic haemophilic synovitis. Haemophilia 2001; 7: 1-5.
33. Siegel HJ, Luck JV Jr, Siegel ME et al. Phosphate-32 colloid radiosynovectomy in hemophilia -outcome of 125 procedures. Clin Orthop 2001; 392: 409-17.
34. Löfqvist T, Petersson C, Nilsson IM. Radioactive synoviorthesis in patients with hemophilia with factor inhibitor. Clin Orthop 1997; 343: 37-41.
35. Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC. Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy. J Thromb Haemost 2005; 3: 1541-2.
36. Dunn AL, Busch MT, Wyly JB, Abshire TC. Radionuclide synovectomy for hemophilic arthropathy: A comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol. Thromb Haemost 2002; 87: 383-93.
37. Ranawat CS, Straub LR, Freyberg R et al. A study of regenerated synovium after synovectomy of the knee in rheumatoid arthritis. Arthritis Rheum 1971; 14: 117-25.
38. Guillemot F. Recent advances in the design of titanium alloys for orthopedic applications. Expert Rev Med Devices 2005; 2: 741-8.
39. Franceschini R, Franceschini M, Romano P et al. Joint replacement in osteoarthritis: State of the art. Semin Arthritis Rheum 2005; 34 (6 Suppl 2): 73-7.
40. National Institute for Clinical Excellence. Guidance on the use of metal on metal hip resurfacing arthroplasty. Technology Appraisal No. 44. June 2002. Available at url: http://www.nice.org.uk/pdf/ HipResurfacing-FinalGuidance.pdf. Accessed on 24 April 2007.
41. Gilbert MS. Surgical management of the adult haemophilic blood cyst (pseutotumour). In: Rodriguez-Merchan EC, Goddard NJ, Lee CA, eds. Musculoskeletal Aspects of Haemophilia. Oxford: Blackwell Science, 2000: 92-6.
42. Quintana-Molina M, Martinez-Bahamonde F, Gonzalez-Garcia E et al. Surgery in haemophilic patients with inhibitor: 20years of experience. Haemophilia 2004;10 (Suppl 2): 30-40.
43. Sheth S, Dimichele D, Lee M et al. Heart transplant in a factor VIII-deficient patient with a high-titre inhibitor: Perioperative management using high-dose continuous infusion factor VIII and recombinant factor VIIa. Haemophilia 2001; 7: 227-32.
44. Gringeri A, Mannucci PM. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
45. Konkle BA, Nelson C, Forsyth A et al. Approaches to successful total knee arthroplasty in haemophilia A patients with inhibitors. Haemophilia 2002; 8: 706-10.
46. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
47. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost 2007; 5: 1577-83.
48. De Kleijn P, Blamey G, Zourikian N et al. Physiotherapy following elective orthopaedic procedures. Haemophilia 2006; 12 (Suppl 3): 108-12.
49. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
50. Teitel J, Poon MC. The safety of recombinant factor VIIa: A rebuttal. J Thromb Haemost 2004; 2: 2078.
51. Shapiro AD, Gilchrist GS, Hoots WK et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
52. Santagostino E, Mancuso ME, Rocino A et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
53. Kenet G, Lubetsky A, Luboshitz J et al. Bolus megadose of recombinant factor VIIa. J Thromb Haemost 2003; 1: 450-5.
54. Ludlam CA, Smith MP, Morfini M et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopedic surgery: A pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
55. Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb Haemost 2007; 98: 726-32.
56. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
57. Berntorp E, Gringeri A, Leissinger C et al. New approaches to using FEIBA in the treatment of inhibitor patients. Semin Thromb Hemost 2006; 32 (Suppl 2): 22-7.
58. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
59. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl 2): 10-6.
60. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
61. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007; 13: 244-8.
62. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006; 134: 314-9.
63. Key NS, Christie B, Henderson N et al. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-5.
64. Bui JD, Despotis GD, Trulock EP et al. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124: 852-4.
65. Rosenfeld SB, Watkinson KK, Thompson BH et al. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-6.
66. Lozier JN, Santagostino E, Kasper CK et al. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors. Semin Hematol 1993; 30 (Suppl 1): 10-21.
67. Hay CR, Lozier JN, Lee CA et al. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: Efficacy, patient selection, and side effects. Semin Hematol 1994; 31 (Suppl 4): 20-5.
68. Stephensen D. Rehabilitation of patients with haemophilia after orthopaedic surgery: A case study. Haemophilia 2005; 11 (Suppl 1): 26-9.
69. Mancuso CA, Sculco TP, Wickiewicz TL et al. Patients'expectations of knee surgery. J Bone Joint Surg Am 2001; 83-A: 1005-12.
70. Sharma L, Sinacore J, Daugherty C et al. Prognostic factors for functional outcome of total knee replacement: A prospective study. J Gerontol A Biol Sci Med Sci 1996; 51: M152-7.
71. Milne S, Brosseau L, Robinson V et al. Continuous passive motion following total knee arthroplasty. Cochrane Database Syst Rev 2003; 2: CD004260.
72. Duarte VM, Fallis WM, Slonowsky D et al. Effectiveness of femoral nerve blockade for pain control after total knee arthroplasty. J Perianesth Nurs 2006; 21: 311-6.
73. Farag E, Dilger J, Brooks P et al. Epidural analgesia improves early rehabilitation after total knee replacement. J Clin Anesth 2005; 17: 281-5.
74. Vanarase MY, Pandit H, Kimstra YW, Dodd CA, Popat MT. Pain relief after knee replacement in patients with a bleeding disorder. Haemophilia 2007; 13: 395-7.
75. Young G, Blain R, Nakagawa P et al. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
76. Baglin T. The measurement and application of thrombin generation. Br J Haematol 2005; 130: 653-61.